Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:Semaxanib
|
| gptkbp:CASNumber |
191732-72-6
|
| gptkbp:category |
protease inhibitor
experimental cancer drug |
| gptkbp:developedBy |
anti-cancer agent
|
| gptkbp:hasMolecularFormula |
C22H18N4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
SU5498
|
| gptkbp:IUPACName |
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-N-(2,6-dimethylphenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
|
| gptkbp:mechanismOfAction |
VEGFR2 tyrosine kinase inhibitor
|
| gptkbp:PubChem_CID |
5329096
CHEMBL19021 |
| gptkbp:status |
investigational drug
|
| gptkbp:studiedBy |
treatment of cancer
|
| gptkbp:target |
gptkb:PDGFR
gptkb:VEGFR2 gptkb:c-Kit |
| gptkbp:bfsParent |
gptkb:Nuneham_Courtenay
|
| gptkbp:bfsLayer |
5
|